Search
JZP-386 free base
go.drugbank.com/drugs/DB17068ExperimentalIts safety, pharmacokinetics and pharmacodynamics were evaluated in clinical trial NCT02215499.
AMB-301
go.drugbank.com/drugs/DB18094ExperimentalAMB-301 is an AAV gene therapy delivering E-selectin.[L48101] It is under investigation for the treatment of Buerger disease.
Col-Treg
go.drugbank.com/drugs/DB18451ExperimentalCol-Treg is an autologous T-cell therapy comprising type I regulatory T-cells specific for human type II collagen.[A261635]
Yeast beta-D-glucan
go.drugbank.com/drugs/DB19271InvestigationalYeast beta-D-glucan is under investigation in clinical trial NCT00632008 (Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers).
Obatoclax
go.drugbank.com/drugs/DB12191InvestigationalObatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.
BGB-DXP593
go.drugbank.com/drugs/DB16357Investigational[L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants
Tasurgratinib
go.drugbank.com/drugs/DB21222InvestigationalThe usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor. … Tasurgratinib is under investigation in clinical trial NCT04962867 (NCCH2006/MK010 Trial (FORTUNE Trial)). Tasurgratinib has a monoisotopic molecular weight of 587.27 Da.
Synonyms: E 7090NSI-189
go.drugbank.com/drugs/DB16230InvestigationalNSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).
AZD-9164
go.drugbank.com/drugs/DB12115InvestigationalAZD9164 has been used in trials studying the basic science and treatment of Chronic Obstructive Pulmonary Disease.
Dianicline
go.drugbank.com/drugs/DB12125InvestigationalDianicline has been used in trials studying the treatment of Smoking, Smoking Cessation, and Tobacco Use Cessation.